| Line 1: |
Line 1: |
| | + | [[File:Dic(9 12).tif|300px]] |
| | + | |
| | ==Myeloproliferative Neoplasms (MPN)== | | ==Myeloproliferative Neoplasms (MPN)== |
| | | | |
| − | *[[Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive]] | + | *[[HAEM5:Chronic myeloid leukaemia]] |
| − | *[[Chronic Neutrophilic Leukemia (CNL)]] | + | *[[HAEM5:Chronic neutrophilic leukaemia]] |
| − | *[[Polycythemia Vera (PV)]] | + | *[[HAEM5:Polycythaemia vera]] |
| − | *[[Primary Myelofibrosis (PMF)]] | + | *[[HAEM5:Primary myelofibrosis]] |
| − | *[[Essential Thrombocythemia (ET)]]
| + | *[[HAEM5:Chronic eosinophilic leukaemia]] |
| − | *[[Chronic Eosinophilic Leukemia, Not Otherwise Specified]] | + | *[[HAEM5:Myeloproliferative neoplasm, NOS]] |
| − | *[[Myeloproliferative Neoplasm (MPN), Unclassifiable]]
| + | *[[Some new stuff]] |
| − | | |
| − | ==Mastocytosis==
| |
| − | | |
| − | *[[Cutaneous Mastocytosis]]
| |
| − | *[[Systemic Mastocytosis]]
| |
| − | *[[Mast Cell Sarcoma]]
| |
| − | | |
| − | ==Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2==
| |
| − | | |
| − | *[[Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement]]
| |
| − | *[[Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement]]
| |
| − | *[[Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement]]
| |
| − | *[[Myeloid/Lymphoid Neoplasms with PCM1-JAK2]]
| |
| − | | |
| − | ==Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)==
| |
| − | | |
| − | *[[Chronic Myelomonocytic Leukemia (CMML)]]
| |
| − | *[[Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative]]
| |
| − | *[[Juvenile Myelomonocytic Leukemia (JMML)]]
| |
| − | *[[Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)|MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)]]
| |
| − | *[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable|MDS/MPN, Unclassifiable]] | |
| − | | |
| − | ==Myelodysplastic Syndromes (MDS)==
| |
| − | | |
| − | *[[Myelodysplastic Syndrome (MDS) with Single Lineage Dysplasia|MDS with Single Lineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)|MDS with Ring Sideroblasts (MDS-RS)]]
| |
| − | *[[Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia|MDS with Ring Sideroblasts and Multilineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Multilineage Dysplasia|MDS with Multilineage Dysplasia]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Excess Blasts|MDS with Excess Blasts]]
| |
| − | *[[Myelodysplastic Syndrome (MDS) with Isolated del(5q)|MSD with Isolated del(5q)]]
| |
| − | *[[Myelodysplastic Syndrome (MDS), Unclassifiable|MDS, Unclassifiable]]
| |
| − | *[[Refractory Cytopenia of Childhood]]
| |
| − | | |
| − | ==Myeloid Neoplasms with Germline Predisposition==
| |
| − | | |
| − | *[[Acute Myeloid Leukaemia with Germline CEBPA Mutation]]
| |
| − | *[[Myeloid Neoplasms with Germline DDX41 Mutation]]
| |
| − | *[[Myeloid Neoplasms with Germline RUNX1 Mutation]]
| |
| − | *[[Myeloid Neoplasms with Germline ANKRD26 Mutation]]
| |
| − | *[[Myeloid Neoplasms with Germline ETV6 Mutation]]
| |
| − | *[[Myeloid Neoplasms with Germline GATA2 Mutation]]
| |
| − | | |
| − | ==Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms==
| |
| − | | |
| − | *[[Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities|AML with Recurrent Genetic Abnormalities]]
| |
| − | | |
| − | - [[Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1|AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11|AML with with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]]
| |
| − | - [[Acute Promyelocytic Leukemia (APL) with PML-RARA]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3|AML with t(9;11)(p21.3;q23.3); KMT2A-MLLT3]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34.1); DEK-NUP214|AML with t(6;9)(p23;q34.1); DEK-NUP214]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM|AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM]]
| |
| − | - [[Acute Myeloid Leukemia (AML) Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1|AML Megakaryoblastic with t(1;22)(p13.3;q13.1);RBM15-MKL1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with BCR-ABL1|AML with BCR-ABL1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Mutated NPM1|AML with Mutated NPM1]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Biallelic Mutations of CEBPA|AML with Biallelic Mutations of CEBPA]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Mutated RUNX1|AML with Mutated RUNX1]]
| |
| − | | |
| − | *[[Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes|AML with Myelodysplasia-Related Changes]]
| |
| − | | |
| − | *[[Therapy-Related Myeloid Neoplasms]]
| |
| − | | |
| − | *[[Acute Myeloid Leukemia (AML), Not Otherwise Specified|AML, Not Otherwise Specified]]
| |
| − | | |
| − | - [[Acute Myeloid Leukemia (AML) with Minimal Differentiation|AML with Minimal Differentiation]]
| |
| − | - [[Acute Myeloid Leukemia (AML) without Maturation|AML without Maturation]]
| |
| − | - [[Acute Myeloid Leukemia (AML) with Maturation|AML with Maturation]]
| |
| − | - [[Acute Myelomonocytic Leukemia]]
| |
| − | - [[Acute Monoblastic and Monocytic Leukemia]]
| |
| − | - [[Pure Erythroid Leukemia]]
| |
| − | - [[Acute Megakaryoblastic Leukemia (AMKL)]]
| |
| − | - [[Acute Basophilic Leukemia]]
| |
| − | - [[Acute Panmyelosis with Myelofibrosis]]
| |
| − | | |
| − | *[[Myeloid Sarcoma]]
| |
| − | | |
| − | *[[Myeloid Proliferations Associated with Down Syndrome]]
| |
| − | | |
| − | - [[Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome]]
| |
| − | - [[Myeloid Leukemia Associated with Down Syndrome]]
| |
| − | | |
| − | ==Blastic Plasmacytoid Dendritic Cell Neoplasm==
| |
| − | | |
| − | *[[Blastic Plasmacytoid Dendritic Cell Neoplasm]]
| |
| − | | |
| − | ==Acute Leukemias of Ambiguous Lineage (MPAL)==
| |
| − | | |
| − | *[[Acute Leukemias of Ambiguous Lineage]] | |
| | | | |
| − | - [[Acute Undifferentiated Leukemia]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL) with t(9;22)(q34.1;q11.2); BCR-ABL1]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL) with t(v;11q23.3); KMT2A Rearranged]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL), B/Myeloid, Not Otherwise Specified]]
| |
| − | - [[Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified]]
| |
| − | - [[Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types]]
| |
| − | - [[Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)]]
| |
| | | | |
| − | ==Precursor Lymphoid Neoplasms (B-ALL, T-ALL)==
| + | '''Primary Author(s)*''' |
| | | | |
| − | *[[B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities|B-Lymphoblastic Leukemia/Lymphoma (B-ALL) with Recurrent Genetic Abnormalities]]
| + | Put your text here |
| | | | |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1|B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1]]
| + | '''Cancer Category/Type''' |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged|B-ALL with t(v;11q23.3); KMT2A-Rearranged]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1|B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy|B-ALL with Hyperdiploidy]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy|B-ALL with Hypodiploidy]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3|B-ALL with t(5;14)(q31.1;q32.1); IGH/IL3]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1|B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like|B-ALL, BCR-ABL1-Like]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma with iAMP21|B-ALL with iAMP21]]
| |
| − | - [[B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified|B-ALL, Not Otherwise Specified]]
| |
| | | | |
| − | *[[T-Lymphoblastic Leukemia/Lymphoma|T-Lymphoblastic Leukemia/Lymphoma (T-ALL)]]
| + | Put your text here |
| | | | |
| − | - [[Early T-Cell Precursor Lymphoblastic Leukemia]]
| |
| − | - [[NK-Lymphoblastic Leukemia/Lymphoma]]
| |
| | | | |
| − | ==Mature B-Cell Neoplasms (CLL, Plasma Cell Neoplasms, Non-Hodgkin Lymphomas)==
| + | '''Cancer Sub-Classification/Subtype''' |
| | | | |
| − | *[[Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma]]
| + | Put your text here |
| | | | |
| − | - [[Monoclonal B-cell Lymphocytosis]]
| |
| | | | |
| − | *[[B-cell Prolymphocytic Leukemia]]
| + | '''Definition/Description of Disease''' |
| | | | |
| − | *[[Splenic Marginal Zone Lymphoma]]
| + | Put your text here |
| | | | |
| − | *[[Hairy Cell Leukemia]]
| |
| | | | |
| − | *[[Splenic B-cell Lymphoma/Leukemia, Unclassifiable]]
| + | '''Synonyms/Terminology''' |
| | | | |
| − | - [[Splenic Diffuse Red Pulp Small B-cell Lymphoma]]
| + | Put your text here |
| − | - [[Hairy Cell Leukemia Variant]]
| |
| | | | |
| − | *[[Lymphoplasmacytic Lymphoma]]
| |
| | | | |
| − | - [[Waldenstrom Macroglobulinemia]]
| + | '''Epidemiology/Prevalence''' |
| | | | |
| − | *[[IgM Monoclonal Gammopathy of Undetermined Significance]]
| + | Put your text here |
| | | | |
| − | *[[Heavy Chain Diseases]]
| |
| | | | |
| − | - [[Mu Heavy Chain Disease]]
| + | '''Clinical Features''' |
| − | - [[Gamma Heavy Chain Disease]]
| |
| − | - [[Alpha Heavy Chain Disease]]
| |
| | | | |
| − | *[[Plasma Cell Neoplasms]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Signs and Symptoms''' |
| | + | |EXAMPLE Asymptomatic (incidental finding on complete blood counts) |
| | | | |
| − | - [[Non-IgM Monoclonal Gammopathy of Undetermined Significance]]
| + | EXAMPLE B-symptoms (weight loss, fever, night sweats) |
| − | - [[Plasma Cell Myeloma]]
| |
| − | - [[Plasma Cell Myeloma Variants]]
| |
| − | - [[Plasmacytoma]]
| |
| − | - [[Monoclonal Immunoglobulin Deposition Diseases]]
| |
| − | - [[Primary Amyloidosis]]
| |
| − | - [[Light Chain and Heavy Chain Deposition Disease]]
| |
| − | - [[Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome]]
| |
| − | - [[POEMS Syndrome]]
| |
| − | - [[TEMPI Syndrome]]
| |
| | | | |
| − | *[[Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)]]
| + | EXAMPLE Fatigue |
| | | | |
| − | *[[Nodal Marginal Zone Lymphoma]]
| + | EXAMPLE Lymphadenopathy (uncommon) |
| | + | |- |
| | + | |'''Laboratory Findings''' |
| | + | |EXAMPLE Cytopenias |
| | | | |
| − | - [[Paediatric Nodal Marginal Zone Lymphoma]]
| + | EXAMPLE Lymphocytosis (low level) |
| | + | |} |
| | | | |
| − | *[[Follicular Lymphoma]]
| |
| | | | |
| − | - [[Testicular Follicular Lymphoma]]
| + | '''Sites of Involvement''' |
| − | - [[In Situ Follicular Neoplasia]]
| |
| − | - [[Duodenal-Type Follicular Lymphoma]]
| |
| | | | |
| − | *[[Paediatric-Type Follicular Lymphoma]]
| + | Put your text here |
| | | | |
| − | *[[Large B-cell Lymphoma with IRF4 Rearrangement]]
| |
| | | | |
| − | *[[Primary Cutaneous Follicle Centre Lymphoma]]
| + | '''Morphologic Features''' |
| | | | |
| − | *[[Mantle Cell Lymphoma]]
| + | Put your text here |
| | | | |
| − | - [[Leukemic Non-Nodal Mantle Cell Lymphoma]]
| |
| − | - [[In Situ Mantle Cell Neoplasia]]
| |
| | | | |
| − | *[[Diffuse Large B-cell Lymphoma, Not Otherwise Specified]]
| + | '''Immunophenotype''' |
| | | | |
| − | *[[T-cell/Histiocyte-Rich Large B-cell Lymphoma]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Positive (universal)''' |
| | + | |EXAMPLE CD1 |
| | + | |- |
| | + | |'''Positive (subset)''' |
| | + | |EXAMPLE CD2 |
| | + | |- |
| | + | |'''Negative (universal)''' |
| | + | |EXAMPLE CD3 |
| | + | |- |
| | + | |'''Negative (subset)''' |
| | + | |EXAMPLE CD4 |
| | + | |} |
| | | | |
| − | *[[Primary Diffuse Large B-cell Lymphoma of the CNS]]
| |
| | | | |
| − | *[[Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type]]
| + | '''Chromosomal Rearrangements (Gene Fusions)''' |
| | | | |
| − | *[[EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Chromosomal Rearrangement''' |
| | + | |'''Genes in Fusion''' |
| | | | |
| − | *[[EBV-Positive Mucocutaneous Ulcer]]
| + | '''(5’ or 3’ Segments)''' |
| | + | |'''Pathogenic Derivative''' |
| | + | |'''Prevalence''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance (Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance (Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE t(9;22)(q34;q11.2) |
| | + | |EXAMPLE 3'ABL1 / 5'BCR |
| | + | |EXAMPLE der(22) |
| | + | |EXAMPLE 20% (COSMIC) |
| | | | |
| − | *[[Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation]]
| + | EXAMPLE 30% (add reference) |
| | + | |Yes |
| | + | |No |
| | + | |Yes |
| | + | |EXAMPLE |
| | | | |
| − | - [[Fibrin-Associated Diffuse Large B-cell Lymphoma]]
| + | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *[[Lymphomatoid Granulomatosis]]
| |
| | | | |
| − | *[[Primary Mediastinal (Thymic) Large B-cell Lymphoma]]
| + | '''Individual Region Genomic Gain/Loss/LOH''' |
| | | | |
| − | *[[Intravascular Large B-cell Lymphoma]]
| + | Put your text here and fill in the table |
| | + | <br /> |
| | + | {| class="wikitable" |
| | + | |'''Chr #''' |
| | + | |'''Gain/Loss/Amp/LOH''' |
| | + | |'''Minimal Region Genomic Coordinates [Genome Build]''' |
| | + | |'''Minimal Region Cytoband''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | *[[ALK-Positive Large B-cell Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance''' |
| | | | |
| − | *[[Plasmablastic Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[Primary Effusion Lymphoma]]
| + | 7 |
| | + | |EXAMPLE Loss |
| | + | |EXAMPLE |
| | | | |
| − | *[[HHV8-Associated Lymphoproliferative Disorders]]
| + | chr7:1- 159,335,973 [hg38] |
| | + | |EXAMPLE |
| | | | |
| − | - [[Multicentric Castleman Disease]]
| + | chr7 |
| − | - [[HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | |Yes |
| − | - [[HHV8-Positive Germinotropic Lymphoproliferative Disorder]]
| + | |Yes |
| | + | |No |
| | + | |EXAMPLE |
| | | | |
| − | *[[Burkitt Lymphoma]]
| + | Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[Burkitt-Like Lymphoma with 11q Aberration]]
| + | 8 |
| | + | |EXAMPLE Gain |
| | + | |EXAMPLE |
| | | | |
| − | *[[High-Grade B-cell Lymphoma]]
| + | chr8:1-145,138,636 [hg38] |
| | + | |EXAMPLE |
| | | | |
| − | - [[High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements]]
| + | chr8 |
| − | - [[High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | |No |
| | + | |No |
| | + | |No |
| | + | |EXAMPLE |
| | | | |
| − | *[[B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma]]
| + | Common recurrent secondary finding for t(8;21) (add reference). |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | ==Mature T- and NK-cell Neoplasms==
| + | '''Characteristic Chromosomal Patterns''' |
| | | | |
| − | *[[T-cell Prolymphocytic Leukemia]]
| + | Put your text here |
| | | | |
| − | *[[T-cell Large Granular Lymphocytic Leukemia]]
| + | {| class="wikitable" |
| | + | |'''Chromosomal Pattern''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | *[[Chronic Lymphoproliferative Disorder of NK Cells]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Therapeutic Significance''' |
| | | | |
| − | *[[Aggressive NK-cell Leukemia]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE |
| | | | |
| − | *[[EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood]]
| + | Co-deletion of 1p and 18q |
| | + | |Yes |
| | + | |No |
| | + | |No |
| | + | |EXAMPLE: |
| | | | |
| − | - [[Systemic EBV-Positive T-cell Lymphoma of Childhood]]
| + | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). |
| − | - [[Chronic Active EBV Infection of T- and NK-cell Type, Systemic Form]]
| + | |- |
| − | - [[Hydroa Vacciniforme-Like Lymphoproliferative Disorder]]
| + | | |
| − | - [[Severe Mosquito Bite Allergy]]
| + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *[[Adult T-cell Leukemia/Lymphoma]]
| |
| | | | |
| − | *[[Extranodal NK/T-cell Lymphoma, Nasal Type]]
| + | '''Gene Mutations (SNV/INDEL)''' |
| | | | |
| − | *[[Intestinal T-cell Lymphoma]]
| + | Put your text here and fill in the table |
| | + | {| class="wikitable" |
| | + | |'''Gene; Genetic Alteration''' |
| | + | |'''Presumed Mechanism (Tumor Suppressor Gene (TSG)/Oncogene/Other)''' |
| | + | |'''Prevalence (COSMIC/ TCGA/Other)''' |
| | + | |'''Concomitant Mutations''' |
| | + | |'''Mutually Exclusive Mutations''' |
| | + | |'''Diagnostic Significance (Yes, No or Unknown)''' |
| | + | |'''Prognostic Significance''' |
| | | | |
| − | - [[Enteropathy-Associated T-cell Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| − | - [[Monomorphic Epitheliotropic Intestinal T-cell Lymphoma]]
| + | |'''Therapeutic Significance''' |
| − | - [[Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)]]
| |
| − | - [[Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract]]
| |
| | | | |
| − | *[[Hepatosplenic T-cell Lymphoma]]
| + | '''(Yes, No or Unknown)''' |
| | + | |'''Notes''' |
| | + | |- |
| | + | |EXAMPLE: TP53; Variable LOF mutations |
| | | | |
| − | *[[Subcutaneous Panniculitis-Like T-cell Lymphoma]]
| + | EXAMPLE: |
| | | | |
| − | *[[Mycosis Fungoides]]
| + | EGFR; Exon 20 mutations |
| | | | |
| − | *[[Sézary Syndrome]]
| + | EXAMPLE: BRAF; Activating mutations |
| | + | |EXAMPLE: TSG |
| | + | |EXAMPLE: 20% (COSMIC) |
| | | | |
| − | *[[Primary Cutaneous CD30 Positive T-cell Lymphoproliferative Disorders]]
| + | EXAMPLE: 30% (add Reference) |
| | + | |EXAMPLE: IDH1 R123H |
| | + | |EXAMPLE: EGFR amplification |
| | + | | |
| | + | | |
| | + | | |
| | + | |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). |
| | + | <br /> |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | + | Note: A more extensive list of mutations can be found in cBioportal (<nowiki>https://www.cbioportal.org/</nowiki>), COSMIC (<nowiki>https://cancer.sanger.ac.uk/cosmic</nowiki>), ICGC (<nowiki>https://dcc.icgc.org/</nowiki>) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. |
| | | | |
| − | - [[Lymphomatoid Papulosis]]
| |
| − | - [[Primary Cutaneous Anaplastic Large Cell Lymphoma]]
| |
| | | | |
| − | *[[Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes]]
| + | '''Epigenomic Alterations''' |
| | | | |
| − | - [[Primary Cutaneous Gamma Delta T-cell Lymphoma]]
| + | Put your text here |
| − | - [[Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma]]
| |
| − | - [[Primary Cutaneous Acral CD8+ T-cell Lymphoma]]
| |
| − | - [[Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder]]
| |
| | | | |
| − | *[[Peripheral T-cell Lymphoma, Not Otherwise Specified (NOS)]]
| + | '''Genes and Main Pathways Involved''' |
| | | | |
| − | *[[Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin]]
| + | Put your text here and fill in the table |
| | + | {| class="wikitable" |
| | + | |'''Gene; Genetic Alteration''' |
| | + | |'''Pathway''' |
| | + | |'''Pathophysiologic Outcome''' |
| | + | |- |
| | + | |EXAMPLE: BRAF and MAP2K1; Activating mutations |
| | | | |
| − | - [[Angioimmunoblastic T-cell Lymphoma]]
| + | EXAMPLE: CDKN2A; Inactivating mutations |
| − | - [[Follicular T-cell Lymphoma]]
| |
| − | - [[Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype]]
| |
| | | | |
| − | *[[Anaplastic Large Cell Lymphoma, ALK-Positive]]
| + | EXAMPLE: KMT2C and ARID1A; Inactivating mutations |
| | + | |EXAMPLE: MAPK signaling |
| | | | |
| − | *[[Anaplastic Large Cell Lymphoma, ALK-Negative]]
| + | EXAMPLE: Cell cycle regulation |
| | | | |
| − | *[[Breast Implant-Associated Anaplastic Large Cell Lymphoma]]
| + | EXAMPLE: Histone modification, chromatin remodeling |
| | + | |EXAMPLE: Increased cell growth and proliferation |
| | | | |
| − | ==Hodgkin Lymphomas==
| + | EXAMPLE: Unregulated cell division |
| | | | |
| − | *[[Nodular Lymphocyte Predominant Hodgkin Lymphoma]]
| + | EXAMPLE: Abnormal gene expression program |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |- |
| | + | | |
| | + | | |
| | + | | |
| | + | |} |
| | | | |
| − | *Classic Hodgkin Lymphoma
| |
| | | | |
| − | - [[Nodular Sclerosis Classic Hodgkin Lymphoma]]
| + | '''Genetic Diagnostic Testing Methods''' |
| − | - [[Lymphocyte-Rich Classic Hodgkin Lymphoma]]
| |
| − | - [[Mixed Cellularity Classic Hodgkin Lymphoma]]
| |
| − | - [[Lymphocyte-Depleted Classic Hodgkin Lymphoma]]
| |
| | | | |
| − | ==Immunodeficiency-Associated Lymphoproliferative Disorders==
| + | Put your text here |
| | | | |
| − | *[[Lymphomas Associated with HIV Infection]]
| |
| | | | |
| − | *[[Post-Transplant Lymphoproliferative Disorders]]
| + | '''Familial Forms''' |
| | | | |
| − | - [[Non-Destructive Post-Transplant Lymphoproliferative Disorders]]
| + | Put your text here |
| − | - [[Polymorphic Post-Transplant Lymphoproliferative Disorders]]
| |
| − | - [[Monomorphic Post-Transplant Lymphoproliferative Disorders (B- and T/NK-cell Types)]]
| |
| − | - [[Monomorphic B-cell PTLD]]
| |
| − | - [[Monomorphic T/NK-cell PTLD]]
| |
| − | - [[Classical Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder]]
| |
| | | | |
| − | *[[Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders]]
| |
| | | | |
| − | ==Histiocytic and Dendritic Cell Neoplasms==
| + | '''Additional Information''' |
| | | | |
| − | *[[Histiocytic Sarcoma]]
| + | Put your text here |
| | | | |
| − | *[[Tumors Derived From Langerhans Cells]]
| |
| | | | |
| − | - [[Langerhans Cell Histiocytosis]]
| + | '''Links''' |
| − | - [[Langerhans Cell Sarcoma]]
| |
| | | | |
| − | *[[Indeterminate Dendritic Cell Tumour]]
| + | Put your text placeholder here (use "Link" icon at top of page) |
| | | | |
| − | *[[Interdigitating Dendritic Cell Sarcoma]]
| |
| | | | |
| − | *[[Follicular Dendritic Cell Sarcoma]]
| + | '''References''' |
| | | | |
| − | - [[Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma]]
| + | (use "Cite" icon at top of page) |
| | | | |
| − | *[[Fibroblastic Reticular Cell Tumor]]
| |
| | | | |
| − | *[[Disseminated Juvenile Xanthogranuloma]]
| + | BOOK EXAMPLE: Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p130-149. |
| | | | |
| − | *[[Erdheim-Chester Disease]]
| + | '''Notes''' |
| | | | |
| − | <comments /> | + | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome. |